Base de dados : MEDLINE
Pesquisa : D02.886.369.939 [Categoria DeCS]
Referências encontradas : 209 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 21 ir para página                         

  1 / 209 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27335428
[Au] Autor:De Bruyne P; Christiaens T; Boussery K; Mehuys E; Van Winckel M
[Ad] Endereço:Department of Paediatrics and Medical Genetics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
[Ti] Título:Are antihistamines effective in children? A review of the evidence.
[So] Source:Arch Dis Child;102(1):56-60, 2017 Jan.
[Is] ISSN:1468-2044
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND AND AIMS: During the last decades, much attention has been paid to off-label and unlicensed prescriptions in paediatrics. However, on-label prescribing can also cause health issues. In this paper, the case of first-generation H -antihistamines is investigated, notably the range of indications for which products are licensed in different European countries and the evidence base (or lack thereof) for each indication, as well as reported adverse drug reactions. METHODS: Review of the Summary of Product Characteristics of first-generation H -antihistamines with a focus on paediatric use. This is plotted against the evidence available in the literature. RESULTS: This investigation shows a large variability in labelled indications and licensing ages when compared in five different European countries. Moreover, most of the indications are not based on clinical trials evaluating efficacy and safety of these drugs in children. CONCLUSIONS: Many of the licensed indications of first-generation antihistamines do not appear to be evidence based.
[Mh] Termos MeSH primário: Antagonistas dos Receptores Histamínicos/uso terapêutico
[Mh] Termos MeSH secundário: Criança
Ciproeptadina/uso terapêutico
Dimetideno/uso terapêutico
Aprovação de Drogas
Rotulagem de Medicamentos
Medicina Baseada em Evidências
Seres Humanos
Uso Off-Label
Resultado do Tratamento
Trimeprazina/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Histamine Antagonists); 2YHB6175DO (Cyproheptadine); 661FH77Z3P (Dimethindene); 76H78MJJ52 (Trimeprazine)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170605
[Lr] Data última revisão:
170605
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:160624
[St] Status:MEDLINE
[do] DOI:10.1136/archdischild-2015-310416


  2 / 209 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26978499
[Au] Autor:Barancevich ER; Golovkova MS; Dzhulaj IA; Posohina OV; Starikov PV
[Ad] Endereço:Almazov Federal North-West Medical Research Centre, St. Petersburg.
[Ti] Título:[The efficacy and safety of teraligen in patients with brain ischemia, stages I and II, and psychoautonomic syndrome].
[So] Source:Zh Nevrol Psikhiatr Im S S Korsakova;115(12):86-91, 2015.
[Is] ISSN:1997-7298
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:OBJECTIVE: To assess the efficacy and safety of teraligen in patients with psychoautonomic syndrome comorbid to brain ischemia. MATERIAL AND METHODS: Forty-five patients, aged from 42 to 65 years (mean age 56 years), diagnosed with brain ischemia, stages I and II, with the signs of psychoautonomic syndrome were examined. Thirty-five patients received teraligen in the daily dose of 15 mg. The control group comprised 10 patients who were not treated with this drug. The duration of treatment was 60 days. Neurological status, autonomic changes, cognitive functions and mental state were assessed during the treatment. Neurophysiological examination (EEG and P300 event-related potential) were performed in the first and last visits. RESULTS AND CONCLUSION: The distinct positive dynamics of the decrease of psychoautonomic symptoms, cephalgic syndrome, sleep normalization as well as the improvement of cognitive function were noted. Good tolerability and no side-effects, in particular, those related to vascular disorders, were demonstrated. Clinical results were supported by the results of neurophysiological examinations. The drug can be recommended for treatment of psychoautonomic syndrome in elderly patients with brain ischemia, stages I and II.
[Mh] Termos MeSH primário: Doenças do Sistema Nervoso Autônomo/tratamento farmacológico
Isquemia Encefálica/tratamento farmacológico
Trimeprazina/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Idoso
Doenças do Sistema Nervoso Autônomo/etiologia
Doenças do Sistema Nervoso Autônomo/fisiopatologia
Isquemia Encefálica/complicações
Isquemia Encefálica/fisiopatologia
Cognição
Potencial Evocado P300
Feminino
Seres Humanos
Masculino
Meia-Idade
Síndrome
Resultado do Tratamento
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
76H78MJJ52 (Trimeprazine)
[Em] Mês de entrada:1604
[Cu] Atualização por classe:170621
[Lr] Data última revisão:
170621
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160316
[St] Status:MEDLINE
[do] DOI:10.17116/jnevro201511511286-91


  3 / 209 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26356157
[Au] Autor:Yakhno NN; Parfenov VA; Reyhart DV; Belostotsky AV; Arnautov VS
[Ad] Endereço:Sechenov First Moscow State Medical University, Moscow.
[Ti] Título:[The multicenter non-interventional, prospective observational program on the study of practical use of teraligen in patients diagnosed with autonomic disorder (START2): a local Russian experience with the use of the Russian version of The Four-Dimensional Symptom Questionnaire (4DSQ). An intermediate analysis].
[So] Source:Zh Nevrol Psikhiatr Im S S Korsakova;115(5):27-33, 2015.
[Is] ISSN:1997-7298
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:AIM: To develop a new instrument able to identify pathological states and assess their changes during medication treatment. We aimed to study the typical practice of using alimemazine (teraligen) in patients with the diagnosis of autonomic nervous system disorder and to test the Russian version of @The Four-Dimensional Symptom Questionnaire@ (4DSQ) for measuring distress, depression, anxiety and somatization. MATERIAL AND METHODS: We examined 3053 patients (mean age 42.09 ± 11.71 years) who received teraligen in doses gradually increasing from 5 to 15 mg per day. The observational program was carried out in over 600 outpatient clinics of the Russian Federation. The 4DSQ was administered before treatment and 4 weeks after treatment. The Clinical Global Impression (CGI) scale was used before, during (after 2 weeks) and after (4 weeks) treatment with teraligen. RESULTS AND CONCLUSION: There was a significant improvement of patient's state assessed both by physicians (CGI scale) and by patients (96 and 98%, respectively). The 4DSQ was sensitive to the parameters of response to treatment with teraligen: parameters obtained at baseline and 4 weeks after the beginning of treatment differed significantly demonstrating a significant decrease in distress, anxiety and somatization.
[Mh] Termos MeSH primário: Doenças do Sistema Nervoso Autônomo/diagnóstico
Doenças do Sistema Nervoso Autônomo/tratamento farmacológico
Inquéritos e Questionários
Trimeprazina/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Ansiedade/diagnóstico
Doenças do Sistema Nervoso Autônomo/psicologia
Depressão/diagnóstico
Prescrições de Medicamentos
Feminino
Seres Humanos
Masculino
Meia-Idade
Federação Russa
[Pt] Tipo de publicação:ENGLISH ABSTRACT; EVALUATION STUDIES; JOURNAL ARTICLE; MULTICENTER STUDY; OBSERVATIONAL STUDY
[Nm] Nome de substância:
76H78MJJ52 (Trimeprazine)
[Em] Mês de entrada:1511
[Cu] Atualização por classe:170621
[Lr] Data última revisão:
170621
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150911
[St] Status:MEDLINE
[do] DOI:10.17116/jnevro20151155127-33


  4 / 209 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25300747
[Au] Autor:Pape E; Roman E; Scala-Bertola J; Thivilier C; Javot L; Saint-Marcoux F; Jouzeau JY; Gambier N
[Ad] Endereço:Department of Clinical Pharmacology and Toxicology, CHU Nancy, Nancy, France.
[Ti] Título:Death of an alcohol-dependent patient following intentional drug intoxication: implication of baclofen?
[So] Source:Eur Addict Res;20(6):300-4, 2014.
[Is] ISSN:1421-9891
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Used in the treatment of spasticity at low doses, baclofen is also prescribed off-label at high doses for the treatment of alcohol dependence. Several cases of baclofen intoxication have been reported, but only 1 case deals with the treatment of alcohol dependence. Thus, we report the first death in the context of baclofen off-label use of an alcohol-dependent patient with a high blood baclofen concentration after intentional drug intoxication. The safety profile of baclofen in the treatment of alcohol dependence is reviewed and discussed, underlining the obligatory caution that may support any prescription of high doses of baclofen in this off-label indication and especially in patients with concomitant psychiatric disorders.
[Mh] Termos MeSH primário: Alcoolismo/tratamento farmacológico
Baclofeno/envenenamento
Overdose de Drogas
Agonistas dos Receptores de GABA-B/envenenamento
[Mh] Termos MeSH secundário: Antipruriginosos/envenenamento
Baclofeno/uso terapêutico
Depressores do Sistema Nervoso Central/envenenamento
Etanol/envenenamento
Evolução Fatal
Agonistas dos Receptores de GABA-B/uso terapêutico
Seres Humanos
Masculino
Meia-Idade
Uso Off-Label
Trimeprazina/envenenamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antipruritics); 0 (Central Nervous System Depressants); 0 (GABA-B Receptor Agonists); 3K9958V90M (Ethanol); 76H78MJJ52 (Trimeprazine); H789N3FKE8 (Baclofen)
[Em] Mês de entrada:1506
[Cu] Atualização por classe:141031
[Lr] Data última revisão:
141031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:141011
[St] Status:MEDLINE
[do] DOI:10.1159/000362409


  5 / 209 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:22747704
[Au] Autor:Genois A; Haig M; Des Roches A; Sirard A; Le May S; McCuaig CC
[Ad] Endereço:Faculty of MedicineDepartments of AnesthesiaServices of Allergy and ImmunologyPediatricsDermatology, CHU Sainte JustineDepartment of Nursing, University of Montreal, Montreal, Quebec, Canada.
[Ti] Título:Case report of atopic dermatitis with refractory pruritus markedly improved with the novel use of clonidine and trimeprazine.
[So] Source:Pediatr Dermatol;31(1):76-9, 2014 Jan-Feb.
[Is] ISSN:1525-1470
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We report a 6-year-old boy with severe atopic dermatitis and refractory pruritus. The novel use of clonidine, an adrenergic agonist, along with trimeprazine, led to dramatic improvement. This represents the first case report of clonidine's effect in relieving pruritus in atopic dermatitis.
[Mh] Termos MeSH primário: Clonidina/uso terapêutico
Dermatite Atópica/tratamento farmacológico
Prurido/tratamento farmacológico
Trimeprazina/uso terapêutico
[Mh] Termos MeSH secundário: Agonistas de Receptores Adrenérgicos alfa 2/uso terapêutico
Antipruriginosos/uso terapêutico
Criança
Dermatite Atópica/patologia
Quimioterapia Combinada
Seres Humanos
Masculino
Uso Off-Label
Prurido/patologia
Índice de Gravidade de Doença
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic alpha-2 Receptor Agonists); 0 (Antipruritics); 76H78MJJ52 (Trimeprazine); MN3L5RMN02 (Clonidine)
[Em] Mês de entrada:1409
[Cu] Atualização por classe:140108
[Lr] Data última revisão:
140108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:120704
[St] Status:MEDLINE
[do] DOI:10.1111/j.1525-1470.2012.01756.x


  6 / 209 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:23886464
[Au] Autor:Auffret M; Béné J; Lachatre M; Lambert M; Gautier S
[Ti] Título:[Neuroleptic malignant syndrome in a patient treated with alimemazine].
[Ti] Título:Syndrome malin des neuroleptiques chez un patient traité par alimémazine..
[So] Source:Therapie;68(3):173-4, 2013 May-Jun.
[Is] ISSN:0040-5957
[Cp] País de publicação:France
[La] Idioma:fre
[Mh] Termos MeSH primário: Hipnóticos e Sedativos/efeitos adversos
Síndrome Maligna Neuroléptica/etiologia
Trimeprazina/efeitos adversos
[Mh] Termos MeSH secundário: Acetaminofen/uso terapêutico
Idoso
Biomarcadores
Confusão/induzido quimicamente
Creatina Quinase/sangue
Emergências
Febre/induzido quimicamente
Febre/tratamento farmacológico
Seres Humanos
Hipnóticos e Sedativos/química
Hipnóticos e Sedativos/uso terapêutico
L-Lactato Desidrogenase/sangue
Masculino
Síndrome Maligna Neuroléptica/sangue
Síndrome Maligna Neuroléptica/tratamento farmacológico
Síndrome Maligna Neuroléptica/psicologia
Distúrbios do Início e da Manutenção do Sono/tratamento farmacológico
Trimeprazina/química
Trimeprazina/uso terapêutico
[Pt] Tipo de publicação:CASE REPORTS; LETTER
[Nm] Nome de substância:
0 (Biomarkers); 0 (Hypnotics and Sedatives); 362O9ITL9D (Acetaminophen); 76H78MJJ52 (Trimeprazine); EC 1.1.1.27 (L-Lactate Dehydrogenase); EC 2.7.3.2 (Creatine Kinase)
[Em] Mês de entrada:1309
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130727
[St] Status:MEDLINE
[do] DOI:10.2515/therapie/2013030


  7 / 209 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:23845695
[Au] Autor:Holdø I; Handal M; Skurtveit S; Bramness JG
[Ad] Endereço:Norwegian Centre for Addiction Research, University of Oslo, Oslo, Norway. holdo@medisin.uio.no
[Ti] Título:Association between prescribing hypnotics for parents and children in Norway.
[So] Source:Arch Dis Child;98(9):732-6, 2013 Sep.
[Is] ISSN:1468-2044
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To describe the dispensing of the hypnotic alimemazine to children aged 0-3 years and investigate the association between dispensing of alimemazine to children and dispensed hypnotics to their parents. DESIGN: An observational cohort study linking information from the Medical Birth Registry of Norway and the Norwegian Prescription Database. Hypnotics dispensed to parents in a 1-year period before pregnancy was associated with dispensed alimemazine for children aged 0-3 years. PATIENTS AND SETTING: All children born in Norway in 2008 (N=59 325) and their mothers and fathers were included. MAIN OUTCOME MEASURES: Dispensed alimemazine to children during the first 3 years of life. RESULTS: Three percent of children received alimemazine. Dispensed hypnotics to mothers increased the risk of the child receiving a prescription for alimemazine, OR of 2.3 (1.7-3.0) for boys and 1.7 (1.2-2.4) for girls. When both parents had been dispensed prescriptions for hypnotics, the risk increased nearly threefold. A dispensed alimemazine prescription was also associated with dispensed prescriptions for antidepressants to both mother and father, mother's smoking, the child's gender and child's prescriptions for antibiotics, respiratory drugs and dermatological steroids. CONCLUSIONS: Dispensed alimemazine to children under 3 was associated with parents' previous use of hypnotics, indicating that factors other than the child's health influence the use of hypnotic drugs in infancy and toddler years. The frequent usage of alimemazine in children below 3 years and the association with parents' use of hypnotics should concern prescribing doctors.
[Mh] Termos MeSH primário: Prescrições de Medicamentos
Hipnóticos e Sedativos/administração & dosagem
Efeitos Tardios da Exposição Pré-Natal/epidemiologia
Trimeprazina/administração & dosagem
[Mh] Termos MeSH secundário: Adulto
Criança
Pré-Escolar
Estudos de Coortes
Feminino
Seres Humanos
Lactente
Masculino
Noruega
Pais
Gravidez
Sistema de Registros
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Hypnotics and Sedatives); 76H78MJJ52 (Trimeprazine)
[Em] Mês de entrada:1311
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:130713
[St] Status:MEDLINE
[do] DOI:10.1136/archdischild-2013-303646


  8 / 209 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:23541943
[Au] Autor:Kumagai H; Suemori H; Uesugi M; Nakatsuji N; Kawase E
[Ad] Endereço:Department of Embryonic Stem Cell Research, Institute for Frontier Medical Sciences, Kyoto University, Shogoin, Kyoto 606-8507, Japan.
[Ti] Título:Identification of small molecules that promote human embryonic stem cell self-renewal.
[So] Source:Biochem Biophys Res Commun;434(4):710-6, 2013 May 17.
[Is] ISSN:1090-2104
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Human embryonic stem cells (hESCs) and induced pluripotent cells have the potential to provide an unlimited source of tissues for regenerative medicine. For this purpose, development of defined/xeno-free culture systems under feeder-free conditions is essential for the expansion of hESCs. Most defined/xeno-free media for the culture of hESCs contain basic fibroblast growth factor (bFGF). Therefore, bFGF is thought to have an almost essential role for the expansion of hESCs in an undifferentiated state. Here, we report identification of small molecules, some of which were neurotransmitter antagonists (trimipramine and ethopropazine), which promote long-term hESC self-renewal without bFGF in the medium. The hESCs maintained high expression levels of pluripotency markers, had a normal karyotype after 20 passages, and could differentiate into all three germ layers.
[Mh] Termos MeSH primário: Proliferação Celular/efeitos dos fármacos
Células-Tronco Embrionárias/citologia
Compostos Orgânicos/farmacologia
Bibliotecas de Moléculas Pequenas
[Mh] Termos MeSH secundário: Animais
Técnicas de Cultura de Células
Diferenciação Celular/efeitos dos fármacos
Linhagem Celular
Células-Tronco Embrionárias/metabolismo
Citometria de Fluxo
Proteínas de Fluorescência Verde/genética
Proteínas de Fluorescência Verde/metabolismo
Seres Humanos
Imuno-Histoquímica
Metotrimeprazina/química
Metotrimeprazina/farmacologia
Camundongos
Camundongos SCID
Estrutura Molecular
Fator 3 de Transcrição de Octâmero/genética
Fator 3 de Transcrição de Octâmero/metabolismo
Compostos Orgânicos/química
Fenotiazinas/química
Fenotiazinas/farmacologia
Células-Tronco Pluripotentes/citologia
Células-Tronco Pluripotentes/metabolismo
Prometazina/química
Prometazina/farmacologia
Trimeprazina/química
Trimeprazina/farmacologia
Trimipramina/química
Trimipramina/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Octamer Transcription Factor-3); 0 (Organic Chemicals); 0 (POU5F1 protein, human); 0 (Phenothiazines); 0 (Small Molecule Libraries); 147336-22-9 (Green Fluorescent Proteins); 6S082C9NDT (Trimipramine); 76H78MJJ52 (Trimeprazine); 7WI4P02YN1 (profenamine); 9G0LAW7ATQ (Methotrimeprazine); FF28EJQ494 (Promethazine)
[Em] Mês de entrada:1308
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130402
[St] Status:MEDLINE


  9 / 209 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:22546247
[Au] Autor:Hasegawa C; Kumazawa T; Terada M; Lee XP; Sato K; Uchigasaki S; Kurosaki K
[Ad] Endereço:Department of Legal Medicine, Toho University School of Medicine, 5-21-16 Omorinishi, Ota-ku, Tokyo 143-8540, Japan. chika99@med.toho-u.ac.jp
[Ti] Título:A new method for quantitative determination of dimemorfan in human plasma using monolithic silica solid-phase extraction tips.
[So] Source:Leg Med (Tokyo);14(5):267-71, 2012 Sep.
[Is] ISSN:1873-4162
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:Dimemorfan was extracted from human plasma samples (100 µL) using MonoTip C(18) tips, which were packed with a C(18)-bonded monolithic silica gel attached to the inside of the tip. The samples, which contained dimemorfan and trimeprazine as an internal standard (IS), were mixed with 300 µL of distilled water and 50 µL of 1M glycine-sodium hydroxide buffer (pH 10). The mixture was extracted onto the C(18) phase of the tip by 20 sequential aspirating/dispensing cycles using a manual micropipettor. The analytes retained on the C(18) phase were then eluted with methanol by five sequential aspirating/dispensing cycles. The eluate was injected directly into a gas chromatograph and detected by a mass spectrometer with selected ion monitoring in positive electron ionization mode. An Equity-5 fused silica capillary column (30 m × 0.32 mm i.d., film thickness 0.25 µm) gave adequate separation of the dimemorfan, IS, and impurities. The recoveries of dimemorfan and the IS spiked into plasma were ≥83%. The regression equation for dimemorfan showed excellent linearity from 0.25 to 32.0 ng/100 µL of plasma, and the limit of detection was 0.125 ng/100 µL of plasma. The maximum intra-day and inter-day relative standard deviations were 13%, while accuracy ranged from 88% to 105%. Dimemorfan was stable for at least 12 h at 4°C, 4 weeks at -80°C, and three freeze-thaw cycles in plasma. This new method is expected to have application as a pretreatment for the rapid, simple, and quantitative determination of dimemorfan in plasma samples.
[Mh] Termos MeSH primário: Morfinanos/análise
Plasma/química
Extração em Fase Sólida/métodos
Trimeprazina/análise
[Mh] Termos MeSH secundário: Antipruriginosos/análise
Antitussígenos/análise
Seres Humanos
Extração em Fase Sólida/instrumentação
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antipruritics); 0 (Antitussive Agents); 0 (Morphinans); 623OAC38YU (dimemorfan); 76H78MJJ52 (Trimeprazine)
[Em] Mês de entrada:1211
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:120502
[St] Status:MEDLINE
[do] DOI:10.1016/j.legalmed.2012.03.004


  10 / 209 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:22311573
[Au] Autor:Sánchez FG; Navas Díaz A; Sánchez Torreño E; Aguilar A; Medina Lama I; Algarra M
[Ad] Endereço:Department of Analytical Chemistry, Faculty of Sciences, University of Malaga, Malaga, Spain. f_garcia@uma.es
[Ti] Título:Determination of enantiomeric excess by chiral liquid chromatography without enantiomerically pure starting standards.
[So] Source:Biomed Chromatogr;26(10):1241-6, 2012 Oct.
[Is] ISSN:1099-0801
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:A facile approach for the enantiomeric excess determination of enantiomeric mixtures without the necessity of pure enantiomer standards is presented. Promethazine and trimeprazine commercial nonracemic mixtures were used as cases study to probe the validity of the method. Chromatographic resolutions obtained with a chiral column AGP in reverse phase mode were 1.32-1.16 (promethazine) and 1.20-0.93 (trimeprazine) for the three detectors (circular dichroism, photometric and fluorimetric) in series. Results obtained showed that enantiomeric excess was 10.4, 8.71 and 8.58% for promethazine and 1.60, 1.23 and 1.80% for trimeprazine (medium values of 9.23 ± 1.01% and 1.54 ± 0.29%, respectively). Recovery assay over human serum samples, at three concentration levels, spiked with prometazine and submitted to solid-phase extraction, gave values of 99.09-93.48% [S-(-) enantiomer] and 98.51-91.89% [R-(+)-enantiomer]. Detection limits of promethazine enantiomers were between 0.02 µg (fluorimetric) and 1 µg (circular dichroism), and 0.02-1.1 µg for trimeprazine.
[Mh] Termos MeSH primário: Cromatografia Líquida/métodos
Cromatografia Líquida/normas
Modelos Químicos
[Mh] Termos MeSH secundário: Dicroísmo Circular
Seres Humanos
Limite de Detecção
Modelos Lineares
Prometazina/química
Padrões de Referência
Reprodutibilidade dos Testes
Estereoisomerismo
Trimeprazina/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
76H78MJJ52 (Trimeprazine); FF28EJQ494 (Promethazine)
[Em] Mês de entrada:1212
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:120208
[St] Status:MEDLINE
[do] DOI:10.1002/bmc.2685



página 1 de 21 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde